Galectin Therapeutics Inc. (GALT) Stock Rating Reaffirmed by Roth Capital
Galectin Therapeutics Inc. (NASDAQ:GALT)‘s stock had its “sell” rating reissued by Roth Capital in a research report issued to clients and investors on Wednesday. They presently have a $0.75 price target on the stock, down from their previous price target of $3.00. Roth Capital’s price target would indicate a potential downside of 38.52% from the stock’s current price.
Several other analysts have also issued reports on the company. FBR & Co restated a “buy” rating on shares of Galectin Therapeutics in a research note on Friday, August 26th. Zacks Investment Research upgraded Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a research note on Monday, August 15th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Galectin Therapeutics in a research note on Thursday, August 4th.
Galectin Therapeutics (NASDAQ:GALT) opened at 1.22 on Wednesday. The firm’s 50-day moving average price is $1.88 and its 200 day moving average price is $1.60. Galectin Therapeutics has a 52-week low of $1.08 and a 52-week high of $3.25. The company’s market cap is $35.72 million.
Galectin Therapeutics (NASDAQ:GALT) last announced its earnings results on Tuesday, August 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.04. On average, equities analysts predict that Galectin Therapeutics will post ($0.89) EPS for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in GALT. Advisor Group Inc. bought a new stake in Galectin Therapeutics during the second quarter worth about $584,000. BlackRock Fund Advisors raised its position in shares of Galectin Therapeutics by 33.8% in the second quarter. BlackRock Fund Advisors now owns 78,955 shares of the company’s stock worth $116,000 after buying an additional 19,967 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Galectin Therapeutics by 0.4% in the second quarter. Vanguard Group Inc. now owns 606,537 shares of the company’s stock worth $892,000 after buying an additional 2,490 shares in the last quarter. Institutional investors own 11.69% of the company’s stock.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Stock Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related stocks with our FREE daily email newsletter.